Odyssey Capital Advisors Inc. Buys New Stake in Stryker Corporation $SYK

Odyssey Capital Advisors Inc. bought a new stake in Stryker Corporation (NYSE:SYK) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,867 shares of the medical technology company’s stock, valued at approximately $656,000.

Several other large investors have also recently bought and sold shares of the business. VanderPol Investments L.L.C. increased its holdings in Stryker by 1.4% in the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after buying an additional 28 shares during the last quarter. Lantz Financial LLC increased its position in shares of Stryker by 5.0% during the third quarter. Lantz Financial LLC now owns 608 shares of the medical technology company’s stock worth $225,000 after purchasing an additional 29 shares in the last quarter. Stonebridge Capital Advisors LLC increased its position in shares of Stryker by 0.4% during the third quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company’s stock worth $2,661,000 after purchasing an additional 29 shares in the last quarter. Tcfg Wealth Management LLC increased its position in shares of Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after purchasing an additional 29 shares in the last quarter. Finally, Mechanics Financial Corp increased its position in shares of Stryker by 1.2% during the fourth quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock worth $864,000 after purchasing an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

NYSE SYK opened at $306.74 on Monday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The business’s 50-day moving average price is $329.68 and its 200 day moving average price is $351.50. The firm has a market cap of $117.59 billion, a P/E ratio of 35.50, a P/E/G ratio of 1.93 and a beta of 0.80.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same period in the prior year, the business earned $2.84 EPS. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities research analysts expect that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Insider Activity

In related news, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 4.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

SYK has been the topic of a number of research analyst reports. Weiss Ratings cut Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Needham & Company LLC cut their target price on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. UBS Group cut their target price on Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 17th. The Goldman Sachs Group reiterated a “neutral” rating and set a $361.00 target price on shares of Stryker in a research report on Friday, May 1st. Finally, Truist Financial reiterated a “hold” rating and set a $330.00 target price (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $395.48.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.